146
Views
98
CrossRef citations to date
0
Altmetric
Original Article

Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro

, &
Pages 401-407 | Received 09 Dec 1996, Accepted 01 Apr 1997, Published online: 08 Jul 2009
 

Abstract

Phospholipase-A2 has been suggested as having a role in the pathophysiology of acute pancreatitis. The inhibition of phospholipase-A2 was studied in vitro using 17 pharmacological agents in the search for a specific therapy for acute pancreatitis. The inhibitory effect was tested using an isotopic assay system with 2-palmitoyl-(1-14C)-labelled dipalmitoyl phosphatidylcholine as a substrate and 10 μ1 of serum from patients with acute necrotizing pancreatitis as an enzyme source. Among all agents tested, anti-inflammatory drugs inhibited enzyme activity most significantly: indomethacin (9.0×10-3 mol 1-1) decreased the phospholipase-A2 activity to one- tenth. The weak inhibitory effect could also be demonstrated using a lower concentration of 2×10-5 mol 1-1, which can be achieved after intravenous administration of 50 mg of this drug. The other drugs inhibited the enzyme activity at concentrations higher than those achieved after intravenous injections in clinical use. Diclofenac (3.1×10-2 mol 1-1) reduced the phospholipase-A2 activity by 93%, ketoprofen (2.0×10-2 mol 1-1) or chlorpromazine (1.4×10-2 mol 1-1) by 90%, tobramycin (1.7×10-2 mol 1-1) by 84%, doxycycline (9.0×10-3 mol 1-1) by 61%, dexamethasone (1.7×10-3 mol 1-1) by 62%, methylprednisolone (3.8×10-2 mol 1-1) by 50%, and pindolol (1.0×10-4 mol 1-1) by 59%. A weak inhibition of phospholipase-A2 activity was demonstrated by betamethasone, bupivacaine, digoxin, hydrocortisone, lidocaine, metoprolol, propranolol, and vancomycin. Indomethacin proved the most potent of the tested agents in inhibiting phospholipase-A2 activity in serum from patients with acute pancreatitis and should be further studied in vivo.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.